Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities CNS Forum on August 19, 2020 at 10:30 a.m. Eastern Time. This event will be held virtually.

The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.

About Minerva Neurosciences

Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.

Contact:William B. BoniVP, Investor Relations/Corp. CommunicationsMinerva Neurosciences, Inc.(617) 600-7376

Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Minerva Neurosciences Charts.
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Minerva Neurosciences Charts.